Table INF-19. Trends in HCV antibody prevalence in national and subnational samples of injecting drug users 2001 to 2006, countries with average prevalence above 50 %.

Country	Notes	2001	2002	2003	2004	2005	2006
Austria DT	1	68	59	44.4	55.8	54.8	37.9
Austria DT	2		66	51	50	58.6	43
Belgium DT	1	79.8	79.5	79.1	76	80.7	78.7
Bulgaria DT	1	44.1	63.1	59	56.5	53.6	52.4
Denmark SP (UAT)					67	58	60.7
Greece DT		67.9	62	67.2	61.2	61.7	66
Italy DT		66.3	64.9	65	63.5	61.4	62
Lithuania DT	1					81.8	70.3
Lithuania DT	2	84.1	89.7	97.4	91	93.7
Norway SP	1	66.9	79	74.2	68.2	69	70.2
Norway SP	2					80.6	78.4
Portugal DT					85.1	84.2	84.8
Romania DT	1			80.6	80.4
Sweden SP	1				81	89.4	83.8
United Kingdom SP (UAT)	1	47	56	55	54	57	56

Notes:

 Countries where the average of trend of available data are above 50 %  

 Seroprevalence studies (SP); diagnostic testing (DT); unlinked anonymous testing (UAT) 

 1 - Austria: data is from Vorarlberg; Belgium: data is from Antwerp; Bulgaria: data is from Sofia; Lithuania: data is from Vilnius; Norway: data is from Oslo; Romania: data is from Bucharest: Sweden: data is from Stockholm; United Kingdom: data is from London. 

 2 - Austria: data is from Vienna, Lower Austria; Lithuania: data is from Alytus city; Norway: National data. 

Related links:

 SB2007: (Figure INF-7) 

 See also 'General notes for interpreting data' on the Explanatory notes and help page. 

 For primary sources and study details, see Table INF-11, and Table INF-0. 

Sources:

 Reitox national focal points  

• Download this data in Excel (.xls) format

(see the help page for information about formats etc.)